La Jolla Pharmaceutical (NASDAQ:LJPC) traded up 7.5% during mid-day trading on Wednesday . The stock traded as high as $11.41 and last traded at $11.20, 495,258 shares traded hands during mid-day trading. A decline of 47% from the average session volume of 932,637 shares. The stock had previously closed at $10.42.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. ValuEngine raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday. Chardan Capital reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Thursday, August 15th. Finally, HC Wainwright set a $27.00 price target on La Jolla Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $15.50.

The company has a market cap of $278.34 million, a price-to-earnings ratio of -1.43 and a beta of 2.17. The firm’s fifty day simple moving average is $9.32 and its 200 day simple moving average is $8.05.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.12) EPS for the quarter, meeting the Zacks’ consensus estimate of ($1.12). La Jolla Pharmaceutical had a negative net margin of 891.53% and a negative return on equity of 715.12%. The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.76 million. Sell-side analysts predict that La Jolla Pharmaceutical will post -4.25 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its holdings in La Jolla Pharmaceutical by 63,657.1% in the first quarter. BNP Paribas Arbitrage SA now owns 4,463 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,456 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in La Jolla Pharmaceutical in the first quarter valued at $32,000. Bank of Montreal Can lifted its holdings in La Jolla Pharmaceutical by 901.3% during the 1st quarter. Bank of Montreal Can now owns 5,537 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 4,984 shares during the last quarter. Red Cedar Capital LLC lifted its holdings in La Jolla Pharmaceutical by 74.6% during the 1st quarter. Red Cedar Capital LLC now owns 11,700 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 5,000 shares during the last quarter. Finally, Calton & Associates Inc. purchased a new stake in La Jolla Pharmaceutical during the 2nd quarter worth about $100,000.

La Jolla Pharmaceutical Company Profile (NASDAQ:LJPC)

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Further Reading: Neutral Rating

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.